RxDoctor Payments Data

Steven Villarreal

Medical · San Antonio, TXNPI 1912318510

Payments from drug & device makers

$2,734in general payments, 2019–2025

Across 130 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$351
  • Almatica Pharma LLC$245
  • Takeda Pharmaceuticals U.S.A., Inc.$114
  • Averitas Pharma Inc.$100
  • Scilex Pharmaceuticals Inc.$89
  • plus $457 from 13 others

What the payments were for

  • Food & beverage$2,734100%
  • Education$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,734 in reported general payments places this provider in the 70th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$150,488
Medicare patients
271
Services billed
3,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lidocaine103$15,924
BelbucaBuprenorphine Hcl23$12,520
Buprenorphine19$7,629
Gabapentin533$6,742
Naloxone Hcl86$5,573
Lidocaine-PrilocaineLidocaine/Prilocaine50$4,347
Pregabalin115$4,334
Tizanidine Hcl192$2,362
Diclofenac Sodium37$1,751
Acetaminophen-CodeineAcetaminophen With Codeine73$1,745
Metaxalone14$1,279
Tramadol Hcl158$1,093
Tramadol Hcl ErTramadol Hcl18$842
Celecoxib56$646
Baclofen75$557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$42$12,52023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,490 medical providers in Texas.

Other medical in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →